Current Oncology Reports

, 16:403

Current Status of Molecular Biomarkers in Endometrial Cancer

Gynecologic Cancers (NS Reed, Section Editor)

DOI: 10.1007/s11912-014-0403-3

Cite this article as:
Werner, H.M.J. & Salvesen, H.B. Curr Oncol Rep (2014) 16: 403. doi:10.1007/s11912-014-0403-3
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers

Abstract

In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as well as promising prognostic and predictive biomarkers in endometrial carcinoma. Key clinical challenges, where use of molecular biomarkers can meet clinical needs, are highlighted. The current status for the presently most promising prognostic and predictive biomarkers in endometrial carcinoma is reviewed. DNA ploidy, p53 status, hormone receptor level, HER2, stathmin, L1 cell adhesion molecule expression and other biomarkers are discussed in relation to the scientific robustness of various essential steps in biomarker development and (current) clinical applicability for individualizing treatment strategies. Tumour heterogeneity and its consequences for biomarker assessment and the importance of developing standardised tests for implementation are discussed. To improve the development and clinical uptake of biomarkers, several strategies are proposed.

Keywords

Endometrial cancerMolecular biomarkersPrognostic biomarkersPredictive biomarkersBiomarker validationClinical utilityGynaecologic cancer

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Clinical ScienceUniversity of BergenBergenNorway
  2. 2.Womens’ ClinicHaukeland University HospitalBergenNorway